Streetbeat News

Analyst Ratings

BNTX

BioNTech (NASDAQ:BNTX) has received mixed analyst ratings over the last three months, with a shift towards a more bullish outlook in the last 30 days. The average 12-month price target for BNTX has been adjusted to $127.5, down from $135.67, reflecting a 6.02% decrease. Analysts from Canaccord Genuity, HC Wainwright & Co., and JP Morgan have updated their ratings and price targets, indicating varied expectations for the company's performance. BioNTech, known for its COVID-19 vaccine Comirnaty and cancer therapeutics, faces challenges in revenue growth and profitability, with a significant revenue decline of -74.13% over the past three months.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 7:00 pm

SNPS

Synopsys (NASDAQ:SNPS) has received mixed analyst ratings over the past three months, with 13 analysts offering evaluations. The ratings include 8 bullish and 5 somewhat bullish, with a notable increase in the average 12-month price target to $622.31 from $571.00, indicating a positive outlook. Analysts from firms like Rosenblatt, Needham, B of A Securities, Wells Fargo, Baird, Stifel, and Keybanc have adjusted their ratings and price targets, reflecting changing market dynamics and company performance. Synopsys's financials show strong revenue growth, net margin, and ROA, but a lower ROE compared to industry averages.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 7:00 pm

JNJ

Deep-pocketed investors have shown a bearish sentiment towards Johnson & Johnson (NYSE:JNJ) based on options trading data from Benzinga. The data reveals a mix of bullish and bearish positions, with a notable lean towards bearishness (55%). Options activity suggests a targeted price range for JNJ between $145.0 and $170.0. The company, a leading healthcare firm, is currently seeing its stock price slightly up at $156.77. Analyst ratings in the last month have set an average target price of $199.0, with varying opinions on the stock's future performance.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 6:45 pm

OXY

Occidental Petroleum (NYSE:OXY) has seen significant unusual options activity, with a bearish sentiment prevailing among big-money traders. Benzinga's options scanner identified 33 unusual trades, with a split sentiment of 33% bullish and 66% bearish. The trades target a price range of $52.5 to $65.0 for OXY over the next 3 months. The largest trades observed were mostly bearish, with both calls and puts involved. Occidental Petroleum is an independent exploration and production company, with its stock price slightly down at $60.5 and analysts giving mixed ratings with an average target price of $70.25.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 6:45 pm

KTOS

Benchmark analyst Josh Sullivan maintains a Buy rating on Kratos Defense & Security (KTOS) and raises the price target from $20 to $25.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 6:43 pm

AMZN

RIVN

Rivian Automotive Inc (NASDAQ:RIVN) is set to report its Q4 financial results, with analysts expecting a significant revenue increase to $1.262 billion from last year's $663.0 million, and a reduced loss of $1.32 per share. Despite beating earnings estimates in recent quarters, several analysts have downgraded RIVN due to the overall weakness in the EV sector and potential challenges in meeting its 2024 gross margin profitability target. Key items for the upcoming earnings include updates on 2024 production, deliveries, and details on the R2 model debut.

Portfolio Pulse from Chris Katje

February 20, 2024 | 6:41 pm

SCHW

Charles Schwab (NYSE:SCHW) has seen a decrease in short interest, with 17.98 million shares sold short, representing 1.08% of its float. This marks a 10.74% decline since the last report. The current short interest suggests a bullish sentiment among investors, as it is lower than the peer group average of 4.91%. Short interest is a key indicator of market sentiment, and a decrease often signals that investors are becoming more optimistic about a stock's future performance.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 6:30 pm

GOLD

Scotiabank analyst Tanya Jakusconek maintains a Sector Outperform rating on Barrick Gold (NYSE:GOLD) but lowers the price target from $24 to $23.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 6:23 pm